Satisfaction and compliance in hormonal contraception: The result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy

被引：7

作者：

Crosignani P.G. ^{[1
]}

Nappi C. ^{[2
,19
]}

Ronsini S. ^{[3
,23
]}

Bruni V. ^{[4
,10
]}

Marelli S. ^{[4
]}

Sonnino D. ^{[5
]}

Affronti G. ^{[6
]}

Benagiano G. ^{[7
]}

Benedetto C. ^{[8
]}

Bolis G. ^{[9
]}

Cianci A. ^{[11
]}

Fedele L. ^{[12
]}

Garsia A. ^{[13
]}

Genazzani A.R. ^{[14
]}

Gherzi R. ^{[15
]}

Masellis G. ^{[16
]}

Melis G. ^{[17
]}

Moscarini M. ^{[18
]}

Piccione E. ^{[20
]}

Quartararo P. ^{[21
]}

Ragni N. ^{[22
]}

Scagliola P. ^{[24
]}

Schönauer S. ^{[25
]}

Sismondi P. ^{[26
]}

Venturini P.L. ^{[27
]}

Volpe A. ^{[28
]}

Zullo F. ^{[29
]}

机构：

[1] II Institute of Obstetrics and Gynaecology, University of Milan, Milan

[2] Department of Obstetric-Gynaecological, Urological Sciences and Reproduction Medicine, University of Naples, Naples

[3] Department of Maternal and Children's Sciences, ASL SA 3 San Luca Hospital, Vallo della Lucania, SA

[4] Department of Gynaecology, Perinatology and Human Reproduction, University of Florence, Florence

[5] Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese, MI

[6] Azienda Ospedaliera di Perugia, Perugia

[7] Università degli Studi di Roma La Sapienza, Roma

[8] Azienda Ospedaliera O.I.R.M.S. Anna, Torino

[9] Azienda Ospedaliera S. Paolo, Milano

[10] Policnico Careggi, Università degli Studi di Firenze, Firenze

[11] Azienda Ospedaliera Universitaria V. Emanuele-Ferrarotto-S. Bambino, Catania

[12] Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano

[13] Azienda Ospedaliera Niguarda Cà Granda, Milano

[14] Università degli Studi di Pisa, Pisa

[15] Azienda Ospedaliera Maggiore della Carità, Novara

[16] Ospedale Civile Ramazzini, Carpi, MO

[17] Ospedale S. Giovanni di Dio, Cagliari

[18] Azienda Ospedaliera S. Andrea, Roma

[19] Università degli Studi Federico II, Napoli

[20] Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma

[21] Policlinico Paolo Giaccone, Palermo

[22] Università degli Studi di Genova, Genova

[23] Ospedale San Luca, Vallo della Lucania, SA

[24] Spedali Civili di Brescia, Brescia

[25] Azienda Ospedaliera Ospedale Policlinico Consorziale, Bari

[26] Azienda Sanitaria Ospedaliera Ordine Mauriziano, Torino

[27] Istituto Giannini Gaslini, Genova

[28] Azienda Ospedaliera di Modena, Modena

[29] Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro

来源：

BMC Women's Health | / 9卷 / 1期

关键词：

Oral Contraceptive; Contraceptive Method; Unintended Pregnancy; Ethinylestradiol; Bioelectrical Impedance Analysis;

D O I：

10.1186/1472-6874-9-18

中图分类号：

学科分类号：

摘要：

Background: For many women finding the right contraceptive method can be challenging and consistent and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be a challenge. The primary objective of this study was to evaluate women's experience with a weekly ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently developed in hormonal contraception to increase women's options in avoiding daily dosing. Methods: In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end, overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated. Results: 175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied. Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred the patch, for convenience (53.9%), ease of use/ simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and the mean subject's compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe and well tolerated: adverse events frequency was low, with predominantly single reports of each event. Most of them started and subsided during cycle 1. Conclusion: This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels and excellent compliance. At study end, the majority of women indicated that they would continue using the patch. © 2009 Crosignani et al; licensee BioMed Central Ltd.

引用

共 37 条

[1]

Petitti D.B., Combination estrogen-progestin oral contraceptives, NEJM, 349, pp. 1443-1450, (2003)

[2]

Kubba A., Guillebaud J., Anderson R.A., MacGregor E.A., Contraception, The Lancet, 356, pp. 1913-1919, (2000)

[3]

Frost J.J., Darroch J.E., Remez L., Improving contraceptive use in the United States, Brief, (2008)

[4]

Rosenberg M.J., Waugh M.S., Burnhill M.S., Compliance, counseling and satisfaction with oral contraceptives: A prospective evaluation, Fam Plann Perspect, 30, pp. 89-92, (1998)

[5]

Rosenberg M.J., Waugh M.S., Meehan T.E., Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation, Contraception, 51, pp. 283-288, (1995)

[6]

Suwanmalee O., Taneepanichskul S., A clinical study of transdermal contraceptive patch in Thai women, J Med Assoc Thai, 89, (2006)

[7]

Prausnitz M.R., Mitragotri S., Langer R., Current status and future potential of transdermal drug delivery, Nature Rev Drug Discov, 3, 2, pp. 115-124, (2004)

[8]

Graziottin A., A review of transdermal hormonal contraception. Focus on the ethinylestradiol/norelgestromin contraceptive patch, Treat Endocrinol, 5, 6, pp. 359-365, (2006)

[9]

Burkman R., Transdermal hormonal contraception: Benefits and risks, Am J Obstet Gynecol, 197, (2007)

[10]

Abrams L.S., Skee D.M., Natarajan J., Wong F.A., Pharmacokinetic overview of Ortho Evra™/Evra™, Fertil Steril, 77, 2 SUPPL. 2, (2002)

← 1 2 3 4 →